Tarsus Pharmaceuticals, Inc. TARS Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s net income?
- Tarsus Pharmaceuticals, Inc. (TARS) reported net income of -$6.97M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s net income changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s net income increased by 72.3% year-over-year, from -$25.12M to -$6.97M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s net income?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s net income has grown at a 48.0% compound annual growth rate (CAGR), from -$13.83M to -$66.42M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.